BLC
ABUS icon

Brown, Lisle/Cummings’s Arbutus Biopharma ABUS Stock Holding History

Brown, Lisle/Cummings’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,500
Closed -$18.8K – 559
2023
Q4 		$18.8K Hold
7,500
– – 0.01% 370
2023
Q3 		$15.2K Hold
7,500
– – 0.01% 360
2023
Q2 		$17.3K Hold
7,500
– – 0.01% 354
2023
Q1 		$22.7K Buy
+7,500
New +$21.2K 0.01% 324

Other funds holding ABUS

WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown, Lisle/Cummings's ABUS Position: Q1 2024 in Review

Brown, Lisle/Cummings sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 7,500 shares — an estimated $18.8K sold.

Brown, Lisle/Cummings first reported a position in ABUS in Q1 2023 and held it in 4 quarters. The position peaked at $22.7K in Q1 2023. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

  • Brown, Lisle/Cummings reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
  • Brown, Lisle/Cummings sold 7,500 Arbutus Biopharma shares in Q1 2024, an estimated $18.8K.
  • Brown, Lisle/Cummings first reported a position in Arbutus Biopharma in Q1 2023 and held it in 4 quarters.
  • Brown, Lisle/Cummings's Arbutus Biopharma position peaked at $22.7K in Q1 2023.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2024, filed 1 Jul 2024.